Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Emergent BioSolutions Inc, Medical Devices Deals, 2012 to YTD 2018 11
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Emergent BioSolutions Acquires ACAM2000 Business from Sanofi 15
Emergent Biosolutions Acquires Raxibacumab from GSK 17
Emergent BioSolutions Acquires Portfolio of Antibiotics from Evolva Holding 19
PaxVax Acquires Vivotif from Crucell 21
Emergent BioSolutions Completes Acquisition Of Healthcare Protective Products Division Of Bracco Diagnostics For US$26 Million 22
Venture Financing 24
PaxVax Raises USD50 Million in Venture Debt Financing 24
PaxVax Raises USD12 Million in Extended Series B Financing 25
PaxVax Raises US$6 Million In Venture Financing 26
PaxVax Raises US$22 Million In Series B Financing 27
Private Equity 28
Cerberus Capital Invests USD105 Million in PaxVax 28
Partnerships 29
CEPI Enters into Partnership with Profectus BioSciences and Emergent BioSolutions 29
CEPI Enters into Collaboration with Profectus BioSciences and Emergent BioSolutions 30
Emergent BioSolutions Enters into Agreement with BARDA 31
PaxVax and TerahVax Korea Enter into Distribution Agreement 32
Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 33
Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 34
PaxVax Enters into Distribution Agreement with Seqirus 35
Emergent BioSolutions Partners with Biomedical Advanced Research and Development Authority 36
Valneva Enters into Distribution Agreement with PaxVax 37
Soligenix Expands its Development Agreement with Emergent BioSolutions 38
PaxVax Enters into Distribution Agreement with BioCSL 39
PaxVax Enters into Distribution Agreement with Novartis 40
PaxVax Enters into Distribution Agreement with Valneva 41
Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 42
Licensing Agreements 44
Emergent BioSolutions Enters into Licensing Agreement with Valneva 44
PaxVax Enters into Licensing Agreement with National Institutes of Health 45
Emergent BioSolutions Enters into Licensing Agreement with Integrated BioTherapeutics 46
PaxVax Enters into Licensing Agreement with Leukocare 47
Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 48
Emergent BioSolutions Amends Licensing Agreement with MorphoSys for ES-414 49
Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 51
PaxVax Enters into Licensing Agreement with University Of California, San Diego 52
Emergent BioSolutions Enters Into Licensing Agreement With VaxInnate For Pandemic Influenza Vaccine 53
Equity Offering 54
Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics 54
Emergent BioSolutions Files Registration Statement For Public Offering Of Securities For US$180 Million 55
Debt Offering 56
Emergent BioSolutions Completes Private Placement Of Notes Due 2021 For US$250 Million 56
Asset Transactions 58
ProMetic Life Sciences Acquires Plasma Collection Center in Canada from Emergent BioSolutions 58
Prokarium Acquires Typhella From Emergent BioSolutions 59
Acquisition 60
Emergent BioSolutions Acquires Adapt Pharma for USD735 Million 60
Emergent BioSolutions Acquires PaxVax from Cerberus Capital Management for USD270 Million 62
Emergent BioSolutions Acquires Unither Virology from United Therapeutics 64
Emergent BioSolutions Completes Acquisition Of Cangene For US$222 Million 65
Emergent BioSolutions Inc – Key Competitors 67
Emergent BioSolutions Inc – Key Employees 68
Emergent BioSolutions Inc – Locations And Subsidiaries 69
Head Office 69
Other Locations & Subsidiaries 69
Joint Venture 71
Recent Developments 72
Strategy And Business Planning 72
Sep 24, 2018: Emergent BioSolutions expands manufacturing capability with ABEC dual purpose single-use microbial fermentation / mammalian cell culture systems 72
Jun 07, 2018: Emergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish Facility 73
May 10, 2017: Emergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufacturing in Baltimore 74
Financial Announcements 76
Aug 02, 2018: Emergent BioSolutions reports financial results for second quarter and six months of 2018 76
May 03, 2018: Emergent BioSolutions Reports First Quarter 2018 Financial Results 79
Feb 22, 2018: Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results 82
Jan 08, 2018: Emergent BioSolutions Announces Preliminary 2017 Financial Results and Provides 2018 Financial Outlook 85
Nov 02, 2017: Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance 86
Aug 03, 2017: Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance 89
May 04, 2017: Emergent BioSolutions Reports First Quarter 2017 Financial Results; Reaffirms 2017 Guidance 92
Feb 23, 2017: Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2016 Financial Results; Reaffirms 2017 Guidance and Provides 2020 Goals 94
Jan 09, 2017: Emergent BioSolutions Announces Preliminary 2016 Financial Results and Provides 2017 Financial Outlook 97
Corporate Communications 98
Mar 26, 2018: Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company’s Growth Strategy 98
Government and Public Interest 99
Feb 13, 2017: Emergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral Hemorrhagic Fever Therapeutics 99
Product News 100
Sep 18, 2017: HHS partners to develop first intranasal treatment for cyanide poisoning 100
Clinical Trials 101
Jan 04, 2018: Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection 101
Other Significant Developments 102
Aug 09, 2018: Ebola virus experts discover powerful, new approach for future therapeutics 102
Appendix 104
Methodology 104
About GlobalData 104
Contact Us 104
Disclaimer 104
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Emergent BioSolutions Inc, Deals By Therapy Area, 2012 to YTD 2018 11
Emergent BioSolutions Inc, Medical Devices Deals, 2012 to YTD 2018 12
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Emergent BioSolutions Acquires ACAM2000 Business from Sanofi 16
Emergent Biosolutions Acquires Raxibacumab from GSK 18
Emergent BioSolutions Acquires Portfolio of Antibiotics from Evolva Holding 20
PaxVax Acquires Vivotif from Crucell 22
Emergent BioSolutions Completes Acquisition Of Healthcare Protective Products Division Of Bracco Diagnostics For US$26 Million 23
PaxVax Raises USD50 Million in Venture Debt Financing 25
PaxVax Raises USD12 Million in Extended Series B Financing 26
PaxVax Raises US$6 Million In Venture Financing 27
PaxVax Raises US$22 Million In Series B Financing 28
Cerberus Capital Invests USD105 Million in PaxVax 29
CEPI Enters into Partnership with Profectus BioSciences and Emergent BioSolutions 30
CEPI Enters into Collaboration with Profectus BioSciences and Emergent BioSolutions 31
Emergent BioSolutions Enters into Agreement with BARDA 32
PaxVax and TerahVax Korea Enter into Distribution Agreement 33
Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 34
Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 35
PaxVax Enters into Distribution Agreement with Seqirus 36
Emergent BioSolutions Partners with Biomedical Advanced Research and Development Authority 37
Valneva Enters into Distribution Agreement with PaxVax 38
Soligenix Expands its Development Agreement with Emergent BioSolutions 39
PaxVax Enters into Distribution Agreement with BioCSL 40
PaxVax Enters into Distribution Agreement with Novartis 41
PaxVax Enters into Distribution Agreement with Valneva 42
Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 43
Emergent BioSolutions Enters into Licensing Agreement with Valneva 45
PaxVax Enters into Licensing Agreement with National Institutes of Health 46
Emergent BioSolutions Enters into Licensing Agreement with Integrated BioTherapeutics 47
PaxVax Enters into Licensing Agreement with Leukocare 48
Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 49
Emergent BioSolutions Amends Licensing Agreement with MorphoSys for ES-414 50
Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 52
PaxVax Enters into Licensing Agreement with University Of California, San Diego 53
Emergent BioSolutions Enters Into Licensing Agreement With VaxInnate For Pandemic Influenza Vaccine 54
Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics 55
Emergent BioSolutions Files Registration Statement For Public Offering Of Securities For US$180 Million 56
Emergent BioSolutions Completes Private Placement Of Notes Due 2021 For US$250 Million 57
ProMetic Life Sciences Acquires Plasma Collection Center in Canada from Emergent BioSolutions 59
Prokarium Acquires Typhella From Emergent BioSolutions 60
Emergent BioSolutions Acquires Adapt Pharma for USD735 Million 61
Emergent BioSolutions Acquires PaxVax from Cerberus Capital Management for USD270 Million 63
Emergent BioSolutions Acquires Unither Virology from United Therapeutics 65
Emergent BioSolutions Completes Acquisition Of Cangene For US$222 Million 66
Emergent BioSolutions Inc, Key Competitors 68
Emergent BioSolutions Inc, Key Employees 69
Emergent BioSolutions Inc, Other Locations 70
Emergent BioSolutions Inc, Subsidiaries 70
Emergent BioSolutions Inc, Joint Venture 72
List of Figures
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Emergent BioSolutions Inc, Medical Devices Deals, 2012 to YTD 2018 12